

Table 6  
(Continued)

Vaccine	Company	Platform	Phase/Status	Primary purpose	Trial description	Location
Inactivated SARS-CoV-2 vaccine (Vero cells) [224]	Beijing Institute of Biological Products/Sinopharm	Inactivated	I/II Recruiting	Prevention	A randomized, double-blind trial N = 21 Study start date: April 28, 2020	China
Inactivated SARS-CoV-2 vaccine [225]	Chinese Academy of Medical Sciences	Inactivated	I/II Recruiting	Prevention	A randomized, parallel assignment, quadruple trial N = 942 Study start date: May 15, 2020	China
Gam-COVID-Vac [226]	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	Non-Replicating Viral Vector	I/II Recruiting	Prevention	A non-randomized, parallel assignment, quadruple trial N = 38 Study start date: June 17, 2020	Russia
Gam-COVID-Vac Lyo [227]	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	Non-Replicating Viral Vector	I/II Recruiting	Prevention	A non-randomized, parallel assignment, quadruple trial N = 38 Study start date: May 15, 2020	Russia
GX-19 [228]	Genexine, Inc.	DNA	I/II Recruiting	Prevention	A randomized, parallel assignment, quadruple masked trial N = 190 Study start date: June 17, 2020	Republic of Korea
Inactivated Vaccine [229]	Beijing Institute of Biological Products/Sinopharm	Inactivated	I/II Recruiting	Prevention	A randomized, parallel assignment trial N = 1448 Study start date: April 11, 2020	China
INO-4800 [230]	Inovio Pharmaceuticals	DNA	I Recruiting	Prevention	A non-randomized, sequential assignment trial N = 40 Study start date: April 3, 2020	USA
NVX-CoV2373 [231]	Novavax	Protein Subunit	I Recruiting	Prevention	A randomized, parallel assignment, triple masked trial N = 131 Study start date: May 25, 2020	Australia
mRNA-1273 [232]	National Institute of Allergy and Infectious Diseases (NIAID)	RNA	I Recruiting	Prevention	A non-randomized, sequential assignment trial N = 155 Study start date: March 16, 2020	USA